An open-label, randomized, phase III trial of zalutumumab, a human monoclonal EGF receptor (EGFr) antibody, versus best supportive care, in patients with noncurable squamous cell carcinoma (SCCHN) of the head and neck who have failed standard platinum-based chemotherapy (ZALUTE).J. H. Machiels, Paul M. Clément, I. Lifrenko et al.|Journal of Clinical Oncology|2010Cited by 13
FinFETs with Thermally Stable RMG Gate Stack for Future DRAM Peripheral CircuitsE. Capogreco, Naoto Horiguchi, Hiroaki Arimura et al.|2022 International Electron Devices Meeting (IEDM)|2022Cited by 10